Use of Androgen Lowering Medications Finasteride and Dutasteride Do Not Substantially Alter Risk of Incident HCV-Related Hepatocellular Carcinoma in Men

    May 2019 in “ Gastroenterology ”
    Donna L. White, Peter J. Richardson, Israel C. Christie … Jennifer R. Kramer
    Studysummary Androgen lowering medications don't significantly change HCV-related liver cancer risk in men.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on gastrojournal.org →
    Discuss this study in the Community →

    Related research 11

    1. Prostate Cancer and Androgenic Alopecia: The Role of Finasteride as a Dual Agent HAMDAN MEDICAL JOURNAL · 2021
    2. The Cardiovascular Safety of Dutasteride ˜The œJournal of urology/˜The œjournal of urology · 2016
    3. Atypical Post-Finasteride Syndrome: A Pharmacological Riddle Indian Journal of Pharmacology · 2016
    4. Current Pharmacological Treatment for Male LUTS Due to BPH: Dutasteride or Finasteride? Current Drug Targets · 2015
    5. Reply to Finasteride and Dutasteride May Reduce Melanoma Risk Cancer · 2015
    6. Finasteride And Dutasteride May Reduce Melanoma Risk Cancer · 2015
    7. Long-Term Use of 5α-Reductase Inhibitors and the Risk of Male Breast Cancer Cancer Causes & Control · 2014
    8. Therapeutic Hotline: Treatment of Androgenic Alopecia with Finasteride May Result in High-Grade Prostate Cancer in Patients: Fact or Fiction? Dermatologic Therapy · 2010
    9. Finasteride: Its Impact on Sexual Function and Prostate Cancer Journal of Cutaneous and Aesthetic Surgery · 2009
    10. Finasteride for Prostatic Disease: An Updated and Comprehensive Review Expert opinion on drug metabolism & toxicology · 2008
    11. Long-Term Experience With 5-Alpha-Reductase Inhibitors PubMed · 2003